Ralf Schierl

Ralf Schierl is a seasoned professional in the biotechnology and biopharmaceutical sectors, with extensive leadership experience since 1992. Ralf Schierl co-founded Zyagnum AG in November 2007, serving as Co-Founder and Vorstand, where the company focuses on developing diagnostic solutions for early detection and treatment of severe diseases, leveraging a profound understanding of immunological processes. In addition, Ralf Schierl has held the position of Geschäftsführer at TAVARGENIX GMBH since 2016, working on the development of an anti-TKTL1 medication for aggressive cancer therapies. Prior roles include serving as Geschäftsführender Gesellschafter at Evomed Medizin Service GmbH from 2001 to 2011, overseeing the development of the leading global ImuPro allergy diagnostic, and managing Innova Labordiagnostik from 1994 to 2001, specializing in infection and allergy diagnostics. Ralf Schierl's career began with the founding of Ralf Schierl Laborfachhandel from 1992 to 1994. Ralf Schierl completed studies at Technische Universität Darmstadt from 1985 to 1991.